Effect of visceral adipose tissue index on hepatocellular carcinoma patients with non-cirrhosis viral hepatitis

Abstract

Abstract: Objective To analyze the risk factors of hepatocellular carcinoma (HCC) in non-cirrhosis patients infected with hepatitis B virus (HBV) and hepatitis C virus (HCV). Methods A total of 212 cases of HBV/HCV-infected HCC patients admitted to Xuzhou Medical University Affiliated Hospital were collected from January 2019 to June 2022. The cases included 143 males and 69 females, with an average age of (65.0±11.8) years. The diagnosis of HCC met the requirements. According to the previous literature, when the FIB-4 index was >3.25, patients with chronic liver disease could be diagnosed with cirrhosis. Based on this, the cases were divided into a non-cirrhosis group and a cirrhosis group. The clinical data of HBV-HCC, HCV-HCC, non-cirrhosis and cirrhosis groups were compared, and multivariate logistic regression analysis was used to identify the factors influencing HCC in non-cirrhosis patients infected by HBV or HCV. Results The average age of HBV-HCC patients was 61.2±11.8 years, with 23 cases (15.9%) having diabetes and 41 cases (28.3%) having hypertension. The Child-Pugh score and FIB-4 index for HBV-HCC patients were 9.0±1.2 and 3.4±0.6, respectively. In comparison, HCV-HCC patients had an average age of 70.1±10.7 years, with 19 cases (28.3%) having diabetes and 29 cases (43.3%) having hypertension. The Child-Pugh score and FIB-4 index for HCV-HCC patients were 5.7±0.9 and 6.2±1.1, respectively. These differences were found to be statistically significant (P<0.05). Additionally, there was a statistically significant difference in tumor staging between HBV-HCC and HCV-HCC patients (P<0.05). Among both non-cirrhosis and cirrhosis patients with HBV-HCC, the visceral adipose tissue index (VATI), Child-Pugh score and HbA1c were significantly different (P< 0.05). Similarly, there were significant differences in sex, VATI, Child-Pugh score and HbA1c between non-cirrhosis and cirrhosis patients with HCV-HCC (P<0.05). Multivariate logistic regression analysis showed that age, male, VATI, HbA1c, hypertension and HBV infection were independent risk factors for HCC in non-cirrhosis patients (P<0.05). Conclusion High VATI, male gender, diabetes, hypertension, and HBV infection are risk factors for HCC in non-cirrhosis patients. It is clinically significant to screen for HCC in patients with non-cirrhosis.

Key words: Hepatocellular carcinoma, Hepatitis B virus, Hepatitis C viru, Visceral adipose tissue index

LI Bo-wen, FEI Su-juan. Effect of visceral adipose tissue index on hepatocellular carcinoma patients with non-cirrhosis viral hepatitis[J]. Chinese Hepatolgy, 2023, 28(10): 1182-1185.

References

[1] Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control,2017,24(3):1073274817729245.
[2] El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol,2002,35(5 Suppl 2):S72-S78.
[3] Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol,2017,67(2):302-309.
[4] Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism,2014,63(5):607-617.
[5] Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res,2019,49(10):1109-1113.
[6] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018,69(1):182-236.
[7] Imai K, Takai K, Nishigaki Y, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res,2010,40(4):376-382.
[8] Imai K, Takai K, Maeda T, et al. Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. Oncotarget,2018,9(18):14058-14067.
[9] Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology,2006,43(6):1317-1325.
[10] Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest,2011,121(6):2094-2101.
[11] Unger RH, Clark GO, Scherer PE, et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta,2010,1801(3):209-214.
[12] Tanaka S, Mohr L, Schmidt EV, et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology,1997,26(3):598-604.
[13] Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev,2000,21(6):697-738.
[14] Imai K, Takai K, Miwa T, et al. Increased visceral adipose tissue and hyperinsulinemia raise the risk for recurrence of non-B non-C hepatocellular carcinoma after curative treatment. Cancers (Basel),2021,13(7):1542.
[15] Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat,2021,28(3):493-507.